| Prof. Ki-hyeong Lee of the hematology–oncology of Chungbuk National University Hospital | |
  CHUNGBUK NATIONAL UNIVERSITY COLLEGE OF MEDICINE
Clinical research in Korea is performed mostly in large hospitals in the metropolitan area, and in recent years, the development of innovative therapies, such as immunotherapy and targeted therapy for lung cancer, has been the main research theme in clinical medicine. Chungbuk National University recognizes the need for academic participation by local universities and has participated in many clinical studies for the development of new medication through the Chungbuk National University Hospital. As an indication of its successful strides in clinical research, Professor Ki-hyeong Lee of Chungbuk National University has been selected as one of the world’s HCR in 2023 in the field of clinical medicine by Clarivate, a global academic information analytics company, for the second consecutive year.
Clarivate is a global academic information analytics company, and recognizes the world’s highly cited researchers, or ‘HCR,’ based on the number of citations on their articles. In response to increasing threats to research integrity, Clarivate applied a new methodology to the evaluation and selection process for the HCR this year. Analysts from the Institute for Scientific Information (ISI) reviewed highly cited papers from the past 10 years and created a preliminary list of candidates. Then they applied enhanced qualitative criteria and metrics to help further narrow down the publications.
Clarivate Criteria for Selection -Researchers must be publishers of the top 1% of cited papers in one of 21 fields in the last 10 years -Selected researchers are considered to be the top 0.1% in the world -6,849 Total researchers -21 Fields of study -65 Koreans from 11 different fields
Rather than it being my personal achievement, it is the result of the dedicated efforts of Chungbuk National University Hospital, the hematology–oncology professors and medical staff, and the research nurse team, who have all been generously supportive of clinical research. Unlike in the past, the level of awareness of clinical research among local patients has greatly increased, and their willingness to participate has also increased, so I am most grateful to the patients and families who participated in our research. — Prof. Ki-hyeong Lee
Research Contributions by Prof. Lee
l Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC DOI: 10.1056/NEJMoa2304594, N Engl J Med - Contributed to a large-scale clinical study that changed the guidelines for post-operative care of patients with EGFR-mutated NSCLC l Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study DOI: 10.1200/JCO.22.01990, J Clin Oncol - Contributed to a large-scale clinical study that changed the guidelines for palliative chemotherapy for patients with NSCLC l Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301 DOI: 10.1200/JCO.23.00515, J Clin Oncol l Lazertinib versus Gefitinib as First-line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset DOI: 10.4143/crt.2023.453, Cancer Res Treat - Contributed to the design and conduct of a large-scale clinical study that changed the guidelines for palliative chemotherapy for patients with EGFR-mutated advanced NSCLC
|
